Synthego Expands Halo Platform Capabilities with Next-Gen Mfg. Facility

Synthego, a genome engineering company, has broken ground on a 20,000-sq.-ft. manufacturing facility designed to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year. The next-generation good manufacturing practices (GMP) factory, an expansion of the Halo Platform, will enable Synthego to significantly expand production of its precision gene editing tools to support a broad panel of nucleases, and meet the needs of biopharma customers developing CRISPR-mediated gene therapies. The new facility is expected to become operational in late 2022, with a significant amount of capacity pre-allocated and prioritized for development partners.
 
“We have a clear vision to make engineered biological therapies accessible to all patients, and an important step on this journey is to ensure that we lead the way with innovations that accelerate the path to the clinic for new therapies,” said Paul Dabrowski, Chief Executive Officer of Synthego. “We designed this facility to deliver our GMP single guide RNA (sgRNA) at scale not only to meet the needs of our biopharma partners, but to drive the industry forward and realize the full potential of the rapidly expanding field of cell and gene therapies.”
 
The facility houses 10,000 sq.-ft. of lab space, including dedicated quality control and R&D labs, 7,000 sq.-ft. of cleanroom space for 24/7 parallel batch production and full redundancy of infrastructure systems allowing partners to quickly scale from early-phase research to process development to clinical research and development activities needed for FDA submissions.